Novartis is returning to an area of medical research that has defeated drug companies time and again over the past decade: diseases of the brain — from depression to Parkinson’s — that affect millions of people worldwide. Steven E. Hyman, professor of stem cell and regenerative biology at FAS, is quoted.
